November 7, 2008

From The News Wire: Reports on Effects of DiabeCell(R)

Living Cell Technologies Reports on 12-Month Clinical Effects of DiabeCell(R) at Annual General Meeting

SYDNEY, Australia & AUCKLAND, New Zealand & BOULDER, Colo., Nov 06, 2008 (BUSINESS WIRE) -- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today updated shareholders at their Annual General Meeting in Adelaide, Australia on the Phase I/IIa clinical trial of DiabeCell(R), LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.

A total of six patients have been implanted with DiabeCell(R) to date; five patients received the lowest dose of 5,000 islet equivalents (IEQ/kg), and one patient was dosed with 10,000 IEQ/kg. Of the initial five patients, four have had a second dose and two patients have been observed for more than 12 months. Of the two patients followed for more than a year, observations include:

Patient one has maintained HbA1c at the ideal level of 6.7 percent with less insulin. His daily insulin dose requirement varies and has been reduced by 25 percent to 46 percent compared to his pre-treatment insulin usage.

Patient two did not require insulin for five months after the first implant and now uses 36 percent less insulin daily than before the DiabeCell(R) implant.

To date there have been no remarkable adverse events.

Click here for more

1 comment :

  1. Geez - I was hoping for better! This was 1 I thought had a chance! And what happened to the drop-out? WHY did they start watching him...hhhmmm